Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 274

1.

[Epithelioid hemangioendothelioma].

Cousin S, Le Loarer F, Crombé A, Karanian M, Minard-Colin V, Penel N.

Bull Cancer. 2018 Dec 4. pii: S0007-4551(18)30340-0. doi: 10.1016/j.bulcan.2018.11.004. [Epub ahead of print] French.

PMID:
30527817
2.

Efficacy and safety of regorafenib in adult patients with metastatic osteosarcoma: a non-comparative, randomised, double-blind, placebo-controlled, phase 2 study.

Duffaud F, Mir O, Boudou-Rouquette P, Piperno-Neumann S, Penel N, Bompas E, Delcambre C, Kalbacher E, Italiano A, Collard O, Chevreau C, Saada E, Isambert N, Delaye J, Schiffler C, Bouvier C, Vidal V, Chabaud S, Blay JY; French Sarcoma Group.

Lancet Oncol. 2018 Nov 23. pii: S1470-2045(18)30742-3. doi: 10.1016/S1470-2045(18)30742-3. [Epub ahead of print]

PMID:
30477937
3.

[Prostate cancer screening: Reasons of controversy].

Delporte G, Villers A, Penel N.

Bull Cancer. 2018 Dec;105(12):1111-1118. doi: 10.1016/j.bulcan.2018.09.007. Epub 2018 Nov 17. French.

PMID:
30458966
4.

Prognostic and predictive factors for angiosarcoma patients receiving paclitaxel once weekly plus or minus bevacizumab: an ancillary study derived from a randomized clinical trial.

Lebellec L, Bertucci F, Tresch-Bruneel E, Ray-Coquard I, Le Cesne A, Bompas E, Blay JY, Italiano A, Mir O, Ryckewaert T, Toiron Y, Camoin L, Goncalves A, Penel N, Le Deley MC.

BMC Cancer. 2018 Oct 11;18(1):963. doi: 10.1186/s12885-018-4828-1.

5.

[Dermatofibrosarcoma: Management].

Penel N, El Bedoui S, Robin YM, Decanter G.

Bull Cancer. 2018 Nov;105(11):1094-1101. doi: 10.1016/j.bulcan.2018.08.008. Epub 2018 Oct 5. Review. French.

PMID:
30297237
6.

[Adjuvant chemotherapy for upper tract urothelial cancer: Level of evidence IA].

Pannier D, Fantoni JC, Turpin A, Penel N.

Bull Cancer. 2018 Oct;105(10):853-854. doi: 10.1016/j.bulcan.2018.07.017. Epub 2018 Sep 17. French. No abstract available.

PMID:
30236478
7.

Localized Myxofibrosarcomas: Roles of Surgical Margins and Adjuvant Radiation Therapy.

Boughzala-Bennadji R, Stoeckle E, Le Péchoux C, Méeus P, Honoré C, Attal J, Duffaud F, De Pinieux G, Bompas E, Thariat J, Leroux A, Bertucci F, Isambert N, Delcambre C, Blay JY, Sunyach MP, Coindre JM, Sargos P, Penel N, Bonvalot S.

Int J Radiat Oncol Biol Phys. 2018 Oct 1;102(2):399-406. doi: 10.1016/j.ijrobp.2018.05.055. Epub 2018 Jun 2.

PMID:
30191871
8.

Once weekly paclitaxel associated with a fixed dose of oral metronomic cyclophosphamide: a dose-finding phase 1 trial.

Pannier D, Adenis A, Bogart E, Dansin E, Clisant-Delaine S, Decoupigny E, Lesoin A, Amela E, Ducornet S, Meurant JP, Le Deley MC, Penel N.

BMC Cancer. 2018 Jul 31;18(1):775. doi: 10.1186/s12885-018-4678-x.

9.

Reappraisal of eligibility criteria in cancer clinical trials.

Penel N, Lebellec L, Vanseymortier M.

Curr Opin Oncol. 2018 Sep;30(5):352-357. doi: 10.1097/CCO.0000000000000470.

PMID:
30020120
10.

[What role for the direct oral anticoagulants in oncology?]

Lebellec L, Kouakam C, Bertrand N, Penel N.

Bull Cancer. 2018 Jul - Aug;105(7-8):631-633. doi: 10.1016/j.bulcan.2018.05.015. Epub 2018 Jun 28. French. No abstract available.

PMID:
29960639
11.

Outcome of 449 adult patients with rhabdomyosarcoma: an observational ambispective nationwide study.

Bompas E, Campion L, Italiano A, Le Cesne A, Chevreau C, Isambert N, Toulmonde M, Mir O, Ray-Coquard I, Piperno-Neumann S, Saada-Bouzid E, Rios M, Kurtz JE, Delcambre C, Dubray-Longeras P, Duffaud F, Karanian M, Le Loarer F, Soulié P, Penel N, Blay JY.

Cancer Med. 2018 Aug;7(8):4023-4035. doi: 10.1002/cam4.1374. Epub 2018 Jun 28. Review.

12.

"Impossible" patients in oncology: Two unusual cases.

Reich M, Tessier W, Lemaire J, Penel N.

Palliat Support Care. 2018 Jun 27:1-3. doi: 10.1017/S147895151800041X. [Epub ahead of print]

PMID:
29947309
13.

Brain Metastases from Adult Sarcoma: Prognostic Factors and Impact of Treatment. A Retrospective Analysis from the French Sarcoma Group (GSF/GETO).

Chaigneau L, Patrikidou A, Ray-Coquard I, Valentin T, Linassier C, Bay JO, Moureau Zabotto L, Bompas E, Piperno-Neumann S, Penel N, Alcindor T, Laigre M, Guillemet C, Salas S, Hugli A, Domont J, Sunyach MP, Lecesne A, Blay JY, Nerich V, Isambert N.

Oncologist. 2018 Aug;23(8):948-955. doi: 10.1634/theoncologist.2017-0136. Epub 2018 Jun 22.

PMID:
29934413
14.

Efficacy and safety of regorafenib compared to placebo and to post-cross-over regorafenib in advanced non-adipocytic soft tissue sarcoma.

Brodowicz T, Mir O, Wallet J, Italiano A, Blay JY, Bertucci F, Eisterer W, Chevreau C, Piperno-Neumann S, Bompas E, Ryckewaert T, Liegl-Antzwager B, Thery J, Penel N, Le Cesne A, Le Deley MC.

Eur J Cancer. 2018 Aug;99:28-36. doi: 10.1016/j.ejca.2018.05.008. Epub 2018 Jun 11.

PMID:
29902612
15.

Ramucirumab Plus Pembrolizumab in Patients with Previously Treated Advanced or Metastatic Biliary Tract Cancer: Nonrandomized, Open-Label, Phase I Trial (JVDF).

Arkenau HT, Martin-Liberal J, Calvo E, Penel N, Krebs MG, Herbst RS, Walgren RA, Widau RC, Mi G, Jin J, Ferry D, Chau I.

Oncologist. 2018 May 31. pii: theoncologist.2018-0044. doi: 10.1634/theoncologist.2018-0044. [Epub ahead of print]

PMID:
29853658
16.

The importance of jointly analyzing treatment administration and toxicity associated with targeted therapies: a case study of regorafenib in soft tissue sarcoma patients.

Longué M, Cabarrou B, Wallet J, Brodowicz T, Roché H, Boher JM, Delord JP, Penel N, Filleron T.

Ann Oncol. 2018 Jul 1;29(7):1588-1593. doi: 10.1093/annonc/mdy168.

PMID:
29722789
17.

Proof of concept: prognostic value of the plasmatic concentration of circulating cell free DNA in desmoid tumors using ddPCR.

Macagno N, Fina F, Penel N, Bouvier C, Nanni I, Duffaud F, Rouah R, Lacarelle B, Ouafik L, Bonvalot S, Salas S.

Oncotarget. 2018 Apr 6;9(26):18296-18308. doi: 10.18632/oncotarget.24817. eCollection 2018 Apr 6.

18.

[Requirement of DPD deficiency screening before prescription of fluoropyrimidines].

Penel N.

Bull Cancer. 2018 Apr;105(4):331-332. doi: 10.1016/j.bulcan.2018.03.001. French. No abstract available.

PMID:
29661375
19.

Nilotinib in locally advanced pigmented villonodular synovitis: a multicentre, open-label, single-arm, phase 2 trial.

Gelderblom H, Cropet C, Chevreau C, Boyle R, Tattersall M, Stacchiotti S, Italiano A, Piperno-Neumann S, Le Cesne A, Ferraresi V, Penel N, Duffaud F, Cassier P, Toulmonde M, Casali P, Taieb S, Guillemaut S, Metzger S, Pérol D, Blay JY.

Lancet Oncol. 2018 May;19(5):639-648. doi: 10.1016/S1470-2045(18)30143-8. Epub 2018 Mar 20.

PMID:
29571946
20.

Non-islet-cell tumour hypoglycaemia (NICTH): About a series of 6 cases.

Jannin A, Espiard S, Benomar K, Do Cao C, Mycinski B, Porte H, D'Herbomez M, Penel N, Vantyghem MC.

Ann Endocrinol (Paris). 2018 Mar 16. pii: S0003-4266(18)30023-4. doi: 10.1016/j.ando.2018.01.005. [Epub ahead of print]

PMID:
29555080

Supplemental Content

Loading ...
Support Center